Irena Mikova

Irena Mikova

Auto-generated profile, based on publicly available information

Irena Mikova

Klinika hepatogastroenterologie, Institut klinické a experimentální medicíny, Praha

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
MBMartin Burian
Martin Burian
MHMilan Hajek
Milan Hajek
PSPetr Sedivy
Petr Sedivy
IMIrena Mikova
Irena Mikova
PTPavel Trunecka
Pavel Trunecka
MDMonika Dezortova
Monika Dezortova
Increased hepatic fat content (HFC) is a hallmark of non-alcoholic fatty liver (NAFL) disease, a common condition in liver transplant recipients. Proton MR spectroscopy (1H MRS) and MR imaging-based proton density fat fraction as the only diagnosis modality enable precise non-invasive measurement of HFC and, also, fatty acid profiles in vivo. Using 1H MRS at 3T, we examined 47 liver transplantation candidates and 101 liver graft recipients. A point-resolved spectroscopy sequence was used to calculate the steatosis grade along with the saturated, unsaturated and polyunsaturated fractions of fatty acids in the liver. The steatosis grade measured by MRS was compared with the histological steatosis grade. HFC, represented by fat fraction values, is adept at distinguishing non-alcoholic steatohepatitis (NASH), NAFL and non-steatotic liver transplant patients. Relative hepatic lipid saturation increases while unsaturation decreases in response to increased HFC. Additionally, relative hepatic lipid saturation increases while unsaturation and polyunsaturation both decrease in liver recipients with histologically proven post-transplant NASH or NAFL compared to non-steatotic patients. HFC, measured by in vivo 1H MRS, correlated well with histological results. 1H MRS is a simple and fast method for in vivo analysis of HFC and its composition. It provides non-invasive support for NAFL and NASH diagnoses.

9 June 2025 in NMR in Biomedicine
Verified
Journal Article
Open access
MHMilan Hajek
Milan Hajek
PSPetr Sedivy
Petr Sedivy
MBMartin Burian
Martin Burian
IMIrena Mikova
Irena Mikova
PTPavel Trunecka
Pavel Trunecka
MDMonika Dezortova
Monika Dezortova
This study investigates the diagnostic accuracy of liver fat fraction (FF) and other biomarkers in differentiating metabolic dysfunction‐associated steatohepatitis (MASH) from non‐MASH conditions in a cohort of 127 liver transplant patients using 1 H MRS and machine learning techniques. Receiver operating characteristic analysis identified FF as the most significant predictor, achieving an area under the curve (AUC) > 0.96 for distinguishing MASH from non‐steatosis and non‐MASH metabolic dysfunction‐associated steatotic liver disease (MASLD). Secondary biomarkers, including insulinemia and elastography, showed moderate discriminatory power (AUC = 0.7–0.8) and contributed to refining classification decisions within a decision tree model. The decision tree analysis, validated with 10‐fold cross‐validation and independent testing, demonstrated robust sensitivity and specificity, with FF contributing 60%–70% to decision‐making. Secondary splits, such as insulinemia (~16.21 μIU/mL) and elastography (~8 kPa), provided additional discriminatory power, particularly in cases with borderline FF values. Non‐significant biomarkers, such as waist circumference and signals of diallylic protons resonating at 2.8 ppm, were excluded due to low discriminatory performance (AUC < 0.7). Compared to the general population (~5.8% prevalence), MASH was significantly more common in liver transplant recipients (~30%–50%). In patients with FF > 5.3%, the positive predictive value (PPV) for MASH ranged from 88% to 97%, more than twice the PPV observed in the general population (approximately 60%). These findings align with existing literature validating MRI‐derived proton density fat fraction as a reliable biomarker for hepatic steatosis. However, liver fat percentage alone is insufficient for MASH diagnosis. Secondary biomarkers, particularly insulinemia and elastography, enhanced classification accuracy near the FF threshold of 5.3%. This multiparametric approach significantly improves diagnostic accuracy and addresses the elevated risk and unique clinical needs of liver transplant recipients. Overall, these results underscore the clinical utility and precision of MR spectroscopy as a noninvasive biomarker for MASH diagnosis in liver transplant patients.

29 August 2025 in Gastroenterologie a hepatologie
Verified
Journal Article
Closed access
IMIrena Míková
Irena Míková
Jana JarosovaJana Jarosova
Jana Jarosova
DCDarina Cupalová
Darina Cupalová
AVAndrea Vajsová
Andrea Vajsová
OFOndrej Fabian
Ondrej Fabian
PTPavel Taimr
Pavel Taimr
Úvod: Kongenitální extrahepatální portosystémový shunt (CEPS; Abernethyho malformace) může být komplikován rozvojem jaterní encefalopatie, plicní hypertenze nebo hepatocelulárního karcinomu (HCC). Prezentujeme případy dvou pacientů s mnohočetným HCC a současným CEPS. Popis případů: Dívka, 17 let, s mohutným portokaválním shuntem byla odeslaná na naše pracoviště pro progredující mnohočetná ložiska jater charakteru FNH/ adenomů dle MR. Cílená bio­psie jednoho z ložisek prokázala hepatocelulární adenom s rizikovými histologickými znaky, nález byl chirurgicky neřešitelný a pacientka byla indikována k transplantaci jater (LT). V průběhu nekomplikované LT byl zrušen portokavální shunt. V explantátu jater byly přítomny mnohočetné adenomy jater, ně­kte­ré již s transformací do dobře diferencovaného HCC. Pacientka je 2,5 roku po LT s dobrou funkcí štěpu, bez recidivy HCC. Muž, 62 let, s mohutným portosystémovým shuntem mezi vena mesenterica superior a vena cava inferior a anamnézou jedné epizody jaterní encefalopatie byl odeslán na naše pracoviště pro CT nález dvou ložisek jater charakteru HCC v terénu pokročilé fibrózy jater (F3 dle elastografie). MR prokázala celkem šest ložisek jater velikosti do 25 mm charakteru HCC, AFP bylo 496 µg/ l. Nález překračoval indikační kritéria IKEM k LT pro HCC a pacient byl indikován k onkologické terapii. Závěr: Abernethyho malformace je spojena se zvýšeným rizikem rozvoje benigních (adenomy) a maligních tumorů (HCC) jater, pečlivá surveillance pacientů je nezbytná.